SCHEMBL1425809

SCHEMBL1425809

CCOc1ccc(C=CC(=O)c2cc(OC)cc(OC)c2)cc1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 2/20 0.70
ABCG2 Q9UNQ0 1/20 0.64
PDE4A P27815 1/20 0.63
PDE4B Q07343 1/20 0.63
PDE4C Q08493 1/20 0.63
PDE4D Q08499 1/20 0.63
TUBB4A P04350 1/20 0.60
TUBB P07437 1/20 0.60
TUBA3C P0DPH7 1/20 0.60
TUBA1B P68363 1/20 0.60
TUBA4A P68366 1/20 0.60
TUBB4B P68371 1/20 0.60
TUBB3 Q13509 1/20 0.60
TUBB2A Q13885 1/20 0.60
TUBB8 Q3ZCM7 1/20 0.60
TUBA3E Q6PEY2 1/20 0.60
TUBA1A Q71U36 1/20 0.60
TUBA1C Q9BQE3 1/20 0.60
TUBB6 Q9BUF5 1/20 0.60
TUBB2B Q9BVA1 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1425807 1.00 CALM1 (0.70) CALM1ABCG2PDE4APDE4BPDE4C
SCHEMBL1425749 0.91 CALM1 (0.67) CALM1ABCG2PDE4APDE4BPDE4C
SCHEMBL1425752 0.91 CALM1 (0.67) CALM1ABCG2PDE4APDE4BPDE4C
SCHEMBL1425750 0.90 CALM1 (0.66) CALM1ABCG2TUBB4ATUBBTUBA3C
SCHEMBL1425753 0.90 CALM1 (0.66) CALM1ABCG2TUBB4ATUBBTUBA3C
SCHEMBL3195266 0.89 CALM1 (0.88) CALM1ABCG2TUBB4ATUBBTUBA3C
SCHEMBL3195246 0.89 CALM1 (0.88) CALM1ABCG2TUBB4ATUBBTUBA3C
SCHEMBL1425136 0.87 TUBB1 (0.81) CALM1ABCG2PDE4APDE4BPDE4C
SCHEMBL1425140 0.87 TUBB1 (0.81) CALM1ABCG2PDE4APDE4BPDE4C
SCHEMBL1425801 0.83 MAOB (0.80) ABCG2MAPTKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432669-B1 4-(C2-6 ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS SPEAR THERAPEUTICS LTD (GB) 2011-03-23 EP disclosed
US-7112698-B2 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents SPEAR THERAPEUTICS LIMITED (GB) 2006-09-26 US disclosed
US-20040259957-A1 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents SPEAR THERAPEUTICS LIMITED (GB) 2004-12-23 US disclosed
EP-1432669-A1 4-(C2-6 ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS Cancer Research Technology Limited (GB) 2004-06-30 EP disclosed
WO-2003029176-A1 4-(C2-6ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2003-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259957-A1 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents OXER1, ALK, BCL6 CALM1 4368/4885ABCG2 191/4885PDE4A 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.